natgillin/translations-raw huggingface dataset:
Enkeltdosishætteglas: 1 hætteglas, der indeholder en enkelt dosis (0,5 ml) til injektion.
Single dose vial: 1 vial containing a single dose (0.5 ml) for injection Instructions for administration of the vaccine:
Studie V87P1 21 dage efter 2. dosis N=149
Study V87P1 21 days after 2nd dose N=149
10 x 10 doser
10 x 10 doses 1 dose (0.5 ml)
- Frekvensen tages op til overvejelse af indehaveren af markedsføringstilladelsen og (Co-)
- Periodicity should be reviewed by the MAH and the (Co-)Rapporteur at 6 monthly intervals.
Studie V87P1 21 dage efter 2. dosis N=37
Study V87P1 21 days after 2nd dose N=37
Studie V87P13 21 dage efter 2. dosis N=210
Study V87P13 21 days after 2nd dose N=210
Natriumchlorid, kaliumchlorid, kaliumdihydrogenphosphat, dinatriumphosphatdihydrat, magnesiumchloridhexahydrat, calciumchloriddihydrat, thiomersal, vand til injektioner.
Sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, thiomersal, water for injections.
Studie V87P13 21 dage efter 2. dosis N=143
Study V87P13 21 days after 2nd dose N=143
Studie V87P13 21 dage efter 2. dosis N=207
Study V87P13 21 days after 2nd dose N=207
- Convulsio:
- Convulsion:
Foclivia injektionsvæske, suspension i flerdosisbeholder Pandemisk influenzavaccine (overfladeantigener, inaktiveret, adjuveret)
Foclivia suspension for injection in multidose container Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted)
Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller hvis du får bivirkninger, som ikke er nævnt her.
Therefore, tell the doctor or nurse if you fainted with a previous injection.
Foclivia injektionsvæske, suspension i fyldt injektionssprøjte Pandemisk influenzavaccine (H5N1) (overfladeantigen, inaktiveret, adjuveret)
Foclivia suspension for injection in pre-filled syringe Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Foclivia injektionsvæske, suspension i fyldt injektionssprøjte Pandemisk influenzavaccine (overfladeantigen, inaktiveret, adjuveret)
Foclivia suspension for injection in pre-filled syringe Pandemic Influenza Vaccine (surface antigen, inactivated, adjuvanted)
Natriumchlorid, kaliumchlorid, kaliumdihydrogenphosphat, dinatriumphosphatdihydrat, magnesiumchloridhexahydrat, calciumchloriddihydrat, vand til injektioner.
Sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate, water for injections.
Kaliumdihydrogenphosphat Dinatriumphosphatdihydrat Magnesiumchloridhexahydrat Calciumchloriddihydrat Thiomersal
Sodium chloride, Potassium chloride, Potassium dihydrogen phosphate, Disodium phosphate dihydrate, Magnesium chloride hexahydrate, Calcium chloride dihydrate, Thiomersal,
Kaliumdihydrogenphosphat, Dinatriumphosphatdihydrat, Magnesiumchloridhexahydrat, Calciumchloriddihydrat, Vand til injektionsvæsker.
Sodium chloride, Potassium chloride, Potassium dihydrogen phosphate, Disodium phosphate dihydrate, Magnesium chloride hexahydrate, Calcium chloride dihydrate, Water for injections.
Enhver anden uønsket hændelse 36 % Unge (9-<18 år)
Fever ≥ 38°C (≥ 40°C) Any Other Adverse Event Adolescents(9-<18 years)
Ikke almindelig: (kan forekomme hos 1-10 ud af 1.000 vaccinerede).
Rare (may affect up to 1 in 1,000 people).
Natriumcitrat
Posology
1113 Budapest, Bocskai út 134-146 Ungarn
AstraZeneca Kft. 1113 Budapest, Bocskai út 134-146 Hungary
FORTEGNELSE OVER LÆGEMIDLERNES NAVNE, LÆGEMIDDELFORM(ER), STYRKE(R), INDGIVELSESVEJ(E), INDEHAVER(E) AF MARKEDSFØRINGSTILLADELSE(R) I MEDLEMSSTATERNE
List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States
AstraZeneca AS Boks 200 Vinderen NO-0319 Oslo, Norge
AstraZeneca AS Boks 200 Vinderen NO-0319 Oslo, Norway
DK-2620 Albertslund, Danmark
DK-2620 Albertslund, Denmark
AstraZeneca GmbH 22876 Wedel, Tyskland
AstraZeneca GmbH 22876 Wedel, Germany
Ronda General Mitre, 151 08022 Barcelona, Spanien
Almirall S.A., Ronda General Mitre, 151 08022 Barcelona, Spain
Grækenland AstraZeneca SA Theotokopoulou 4 & Astronafton 151 25 Maroussi
AstraZeneca SA Theotokopoulou 4 & Astronafton 151 25 Maroussi Greece
AstraZeneca Österreich GmbH., Schwarzenbergplatz 7, A-1037 Wien, Østrig
AstraZeneca Österreich GmbH., Schwarzenbergplatz 7, A-1037 Wien, Austria
Palazzo Volta-via F Sforza - 20080 Basiglio (MI) - Italien
AstraZeneca SpA Palazzo Volta-via F Sforza - 20080 Basiglio (MI)Italy
1, Place Renault 92844 Rueil-Malmaison Cedex Frankrig
AstraZeneca 1, Place Renault 92844 RueilMalmaison Cedex France
AstraZeneca UK Limited 15 Stanhope Gate London W1K 1LN Storbritannien
15 Stanhope Gate London W1K 1LN United Kingdom
AstraZeneca UK Limited, 600 Capability Green, Luton, LU1 3LU, Storbritannien
Capability Green, Luton, LU1 3LU, United Kingdom
Takeda Pharma GmbH, Viktoriaallee 3-5, 52066 Aachen, Tyskland
Viktoriaallee 3-5, 52066 Aachen, Germany
Laboratoires Takeda, 11-15, quai de Dion Bouton, 92816 Puteaux Cedex, Frankrig
Laboratoires Takeda, 11-15, quai de Dion Bouton,
AstraZeneca AB, Strängnäsvägen 44, S-151 85 Södertälje, Sverige
AstraZeneca AB, Strängnäsvägen 44, S-151 85 Södertälje, Sweden
AstraZeneca BV Louis Pasteurlaan 5 2719 EE Zoetermeer Holland
Netherlands AstraZeneca BV Louis Pasteurlaan 5
AstraZeneca AB 151 85 Södertälje, Sverige
AstraZeneca AB 151 85 Södertälje, Sweden
Lusomedicamenta - Sociedade Técnica Farmacêutica, S.A. Estrada Consiglieri Pedroso, 69 BQueluz de Baixo
LusomedicamentaSociedade Técnica Farmacêutica, S.A. Estrada Consiglieri Pedroso, 69 BQueluz de Baixo 2730-055 Barcarena, Portugal
AstraZeneca AB, S-151 85 Södertälje, Sverige
AstraZeneca AB, S151 85 Södertälje, Sweden
Lusomedicamenta - Sociedade Técnica Farmacêutica, S.A., Estrada Consiglieri Pedroso, 69 BQueluz de Baixo
LusomedicamentaSociedade Técnica Farmacêutica, S.A., Estrada Consiglieri Pedroso, 69 BQueluz de Baixo 2730-055 Barcarena, Portugal
2730-055 Barcarena, Portugal
28033 Madrid, Spain
Storbritannien
United Kingdom.
NV AstraZeneca SA Egide Van Ophemstraat 110 B-1180 Brussels Belgien
B-1180 Brussels
AstraZeneca SpA
AstraZeneca UK Limited
Atacand Plus 32 mg/12.5 mg
Ratacand Plus 32 mg / 12.5 mg
Atacand Zid 16mg / 12,5 mg 16 mg/12,5 mg Tablet
Atacand Zid 16mg / 12.5 mg
Atacand Plus 16 mg/12.5 mg
Atacand Plus 16/12.5 mg
CoKenzen 16mg/12,5mg comprimé
16mg/12,5mg comprimé
Parapres Plus Forte 32mg/25mg comprimidos
32mg/25mg comprimidos
Blopress Plus 32mg/ 12,5mg - Tabletten
Blopress Plus 32mg/ 12,5mgTabletten
Blopress Plus 16mg/12.5mg - Tabletten
Blopress Plus 16mg/12.5mgTabletten
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Hexyon den 17. april 2013.
The European Commission granted a marketing authorisation valid throughout the European Union for Hexyon on 17 April 2013.
Hexyon er en vaccine.
Hexyon is a vaccine.
Den fuldstændige EPAR for Hexyon findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Hexyon can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Hexyon.
This is a summary of the European public assessment report (EPAR) for Hexyon.
Vaccination med Hexyon bør foretages i henhold til officielle anbefalinger.
Vaccination with Hexyon should be carried out according to official recommendations.
Andre oplysninger om Hexyon
Other information about Hexyon
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Hexyon?
What measures are being taken to ensure the safe and effective use of Hexyon?
Vaccinationsplanen med to doser blev undersøgt i en yderligere hovedundersøgelse hos 554 børn.
The two-dose vaccination schedule was investigated in an additional main study involving 554 children.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Hexyon opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Hexyon's benefits are greater than its risks and recommended that it be approved for use in the EU.
Hvorfor blev Hexyon godkendt?
Why is Hexyon approved?
Hexyon indeholder små mængder af materialer, der stammer fra bakterien og virusset, som det beskytter imod.
Hexyon contains small amounts of materials derived from the bacteria and viruses it protects against.
Det er ikke en praktisk vejledning i, hvordan Hexyon bør anvendes.
It is not intended to provide practical advice on how to use Hexyon.
Hvad er Hexyon, og hvad anvendes det til?
What is Hexyon and what is it used for?
Med hensyn til sikkerheden fandt CHMP, at Hexyons sikkerhedsprofil overordnet svarer til andre vacciners, omend der er større sandsynlighed for, at vaccination med Hexyon i forhold til lignende vacciner vil fremkalde reaktioner (hovedsagelig på injektionsstedet).
Regarding safety, the CHMP considered that Hexyon's overall safety profile is similar to other vaccines, although vaccination with Hexyon is more likely than similar vaccines to cause reactions (mainly at the injection site).
Hexyon er blevet undersøgt i en række lande over hele verden i 12 hovedundersøgelser med over 3 400 børn mellem seks uger og to år gamle, der fik tre doser af vaccinen inden seksmåneders alderen i henhold til forskellige lokale vaccinationsplaner.
Hexyon has been studied in several countries worldwide in 12 main studies involving over 3,400 children between six weeks and two years of age who were given three doses of the vaccine during their first six months of life according to different local vaccination schedules.
Virkningen blev sammenlignet med en kombination af separate vacciner mod de sygdomme, der dækkes af Hexyon.
The effects were compared with a combination of separate vaccines designed to protect against the diseases included in Hexyon.
Hvilken risiko er der forbundet med Hexyon?
What are the risks associated with Hexyon?
Hexyon gives ved dyb indsprøjtning i en muskel, sædvanligvis i den øverste del af låret eller i skulderen.
Hexyon is given by deep injection into a muscle, normally in the upper thigh or the shoulder.
Hvis du ønsker yderligere oplysninger om behandling med Hexyon, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
For more information about treatment with Hexyon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Hexyon må ikke anvendes til børn, som tidligere har haft en allergisk reaktion over for Hexyon eller en vaccine, der indeholder de samme komponenter, herunder stoffer, der anvendes ved fremstilling af vaccinen og som muligvis kan forefindes i ekstremt små mængder (som f.eks. antibiotikaene neomycin eller streptomycin).
Hexyon must not be used in children who have ever had an allergic reaction to Hexyon or a vaccine containing the same components, including substances used during the manufacture of the vaccine and which may be found at extremely low levels (such as the antibiotics neomycin or streptomycin).
Undersøgelserne viste, at Hexyon frembringer antistofdannelse med samme forløb over tid som andre tilsvarende vacciner, og at vaccinen kan gives samtidig med Prevenar og Rotarix.
These studies showed that Hexyon produces similar antibody profiles over time to comparable vaccines, and that the vaccine can be given at the same time as Prevenar and Rotarix.
De hyppigste bivirkninger ved Hexyon er smerter og rødme på injektionsstedet, irritabilitet og grådreaktion.
The most common side effects with Hexyon include pain and redness at the site of injection, irritability and crying.
CHMP bemærkede, at Hexyon har vist sig at udvikle beskyttende antistofniveauer mod difteri, stivkrampe, kighoste, hepatitis B, poliomyelitis og H. influenzae type b-infektioner hos børn mellem seks uger og to år uanset etnisk oprindelse.
The CHMP noted that Hexyon has been shown to produce protective antibody levels against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and H. influenzae type b infections in children between six weeks and two years of age regardless of ethnicity.
Hvis du ønsker praktisk vejledning om anvendelsen af Hexyon, kan du læse indlægssedlen eller kontakte din læge eller dit apotek.
For practical information about using Hexyon, patients should read the package leaflet or contact their doctor or pharmacist.
Som boosterdosis kan anvendes Hexyon eller en passende kombination af andre vacciner.
Hexyon or an appropriate combination of other vaccines can be used for the booster dose.
Hvordan anvendes Hexyon?
How is Hexyon used?
Hexyon må ikke anvendes hos børn, der tidligere har fået encefalopati (en hjernesygdom) af ukendt årsag inden for syv dage efter at være blevet vaccineret med en vaccine indeholdende komponenter af kighoste (pertussis).
It must not be used in children who have ever had encephalopathy (a brain disease) of unknown cause within seven days of receiving a vaccine containing pertussis components in the past.
Den fuldstændige liste over indberettede bivirkninger ved Hexyon fremgår af indlægssedlen.
For the full list of all side effects reported with Hexyon, see the package leaflet.
I denne undersøgelse udløstes der hos de børn, der fik Hexyon, en antistofrespons, der svarede til antistofresponsen hos de børn, der fik en sammenligningsvaccine (Infanrix hexa), når vaccinen blev givet som en todosisplan efterfulgt af en boostervaccine seks måneder senere.
In the study, children who either received Hexyon produced a similar antibody response to those who received a comparator vaccine (Infanrix hexa), when given as a two-dose schedule followed by a booster 6 months later.
Hexyon er en vaccine, der indeholder aktive stoffer afledt af difteri-, stivkrampe-, kighoste- og Haemophilus influenzae type b-bakterier, hepatitis B-virus og inaktiverede poliovirusser.
Hexyon is a vaccine containing active substances derived from diphtheria, tetanus, pertussis and Haemophilus influenzae type b bacteria, the hepatitis B virus, and inactivated polioviruses.
Hvilke fordele viser undersøgelserne, at der er ved Hexyon?
What benefits of Hexyon have been shown in studies?
Hos børn med moderat til svær feber bør vaccination med Hexyon udsættes.
Vaccination with Hexyon should be postponed if a child has a moderate to severe fever.
Undersøgelserne viste, at der hos mellem 90 % og 100 % af børnene blev dannet en beskyttende mængde antistoffer mod de forskellige sygdomme efter de første tre doser af Hexyon.
The studies showed that protective antibody levels against the various diseases developed in between 90 and 100% of children after the first three doses of Hexyon; protection was maintained or improved when a booster dose was given.
I produktresuméet og indlægssedlen er der indføjet anbefalinger og forholdsregler, som sundhedspersonale og patienter skal følge med henblik på sikker og effektiv anvendelse af Hexyon.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Hexyon have been included in the summary of product characteristics and the package leaflet.
Hvordan virker Hexyon?
How does Hexyon work?
Hexyon leveres som injektionsvæske (suspension) i hætteglas og fyldte sprøjter.
Hexyon is available as a suspension for injection in vials and prefilled syringes.
Endnu en undersøgelse med 1 336 børn vedrørte virkningen af forskellige vaccinebatcher (produktionsserier), og hvad der skete, når vaccinen blev givet sammen med vacciner mod bakterien Streptococcus pneumoniae (Prevenar) og rotavirus (Rotarix).
A subsequent study involving 455 children looked at the longer-term persistence of protective antibodies up to 3 years after a booster dose with Hexyon, and another study in 1,336 children evaluated the response to different lots of the vaccine and what happened when it was given with vaccines for infections caused by the bacterium Streptococcus pneumoniae (Prevenar) and rotavirus (Rotarix).
Behandlingen fortsættes, så længe sygdommen ikke forværres.
Treatment is continued for as long as the disease is not getting worse.
Lynparza fik en markedsføringstilladelse med gyldighed i hele EU den 16. december 2014.
Lynparza received a marketing authorisation valid throughout the EU on 16 December 2014.
Yderligere information om Lynparza findes på agenturets websted under: ema.europa.eu/medicines/human/EPAR/lynparza.
Further information on Lynparza can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/lynparza.
Lynparza findes som tabletter (100 og 150 mg) og kapsler (50 mg), som patienten tager to gange dagligt.
Lynparza is available as tablets (100 and 150 mg) and capsules (50 mg) which the patient takes twice a day.
Lynparza er et kræftlægemiddel, der anvendes alene til:
Lynparza is a cancer medicine used on its own for:
Lynparza indeholder det aktive stof olaparib.
Lynparza contains the active substance olaparib.
Derudover kan tabletterne tages sammen med mad eller mellem måltider, mens kapslerne bør tages mindst 1 time efter et måltid, hvorefter patienterne ikke bør spise i 2 timer.
Furthermore, while tablets can be taken with food or between meals, the patient should take the capsules at least 1 hour after food and not eat for up to 2 hours afterwards.
Som for alle lægemidler bliver data vedrørende brugen af Lynparza løbende overvåget.
As for all medicines, data on the use of Lynparza are continuously monitored.
Andre oplysninger om Lynparza
Other information about Lynparza
Kvinder må ikke amme under behandlingen med Lynparza og i en måned efter behandlingen.
Women must not breastfeed during treatment with Lynparza and for a month after stopping treatment.
Bivirkningerne ved Lynparza var typisk milde eller moderate og var generelt håndterbare.
The side effects with Lynparza were mostly mild or moderate and were generally manageable.
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Lynparza?
What measures are being taken to ensure the safe and effective use of Lynparza?
Det Europæiske Lægemiddelagentur konkluderede derfor, at fordelene ved Lynparza opvejer risiciene, og at det kan godkendes til anvendelse i EU.
The European Medicines Agency therefore decided that Lynparza's benefits are greater than its risks and it can be authorised for use in the EU.
Lynparza fås kun på recept, og behandlingen bør indledes og overvåges af en læge med erfaring i brug af kræftlægemidler.
Lynparza can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
Når PARP-proteinerne således blokeres, kan de ikke reparere det beskadigede dna i kræftcellerne, og derfor dør kræftcellerne.
Therefore, when PARP proteins are blocked, the damaged DNA in cancer cells cannot be repaired, and, as a result, the cancer cells die.
Lynparza kan forlænge den tid, som disse patienter lever uden sygdomsforværring.
Lynparza can increase the time these patients live without their disease getting worse.
De hyppigste bivirkninger ved Lynparza (som kan forekomme hos mere end 1 ud af 10 personer) er træthed, kvalme, opkastning, diarré, halsbrand, hoste, hovedpine, smagsforstyrrelser, nedsat appetit, svimmelhed, mavesmerter, vejrtrækningsbesvær, blodmangel (lavt antal røde blodlegemer), leukopeni (lavt antal hvide blodlegemer), neutropeni (lavt antal af en bestemt type hvide blodlegemer, der bekæmper infektioner) og trombocytopeni (lavt antal blodplader).
The most common side effects with Lynparza (which may affect more than 1 in 10 people) are tiredness, nausea (feeling sick), vomiting, diarrhoea, dyspepsia (heartburn), cough, headache, dysgeusia (taste disturbances), decreased appetite, dizziness, upper abdominal pain (stomach ache), dyspnoea (difficulty breathing), anaemia (low red blood cell counts), leucopenia (low white blood cell counts), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection) and thrombocytopenia (low blood platelet counts).
Bivirkninger rapporteret for Lynparza vurderes omhyggeligt, og der foretages nødvendige forholdsregler for at beskytte patienterne.
Side effects reported with Lynparza are carefully evaluated and any necessary action taken to protect patients.
Dosen og valget mellem Lynparza-kapsler og -tabletter afhænger af, hvilken sygdom der skal behandles.
The dose and the choice between capsules and tablets of Lynparza depends on what disease it is being used for.
Ved fremskreden kræft i æggestokkene kan lægen stoppe behandlingen efter 2 år, hvis en røntgenundersøgelse ikke viser tegn på kræft.
In advanced ovarian cancer, the doctor may stop treatment after 2 years if X-rays show no signs of the cancer.
En oversigt over Lynparza, og hvorfor det er godkendt i EU
An overview of Lynparza and why it is authorised in the EU
Det aktive stof i Lynparza, olaparib, blokerer virkningen af enzymer, der kaldes humane poly-(ADPribose)-polymeraser (PARP'er), som hjælper med at reparere beskadiget dna i cellerne (både normale celler og kræftceller) under celledelingen.
The active substance in Lynparza, olaparib, blocks the action of enzymes called human poly (ADP ribose) polymerase (PARP), which help to repair damaged DNA in cells (both in normal and in cancer cells) during cell division.
Virksomheden, der markedsfører Lynparza, vil udføre studier for yderligere at bekræfte fordelen, herunder på lang sigt, hos patienter med kræft i æggestokkene.
The company that markets Lynparza will carry out studies to further confirm the benefit, including long-term benefit, of the medicine in patients with ovarian cancer.
Hvis du ønsker mere information om anvendelsen af Lynparza, kan du læse indlægssedlen eller kontakte lægen eller apotekspersonalet.
For more information about using Lynparza, see the package leaflet or contact your doctor or pharmacist.
Hvis der optræder visse bivirkninger, kan behandlingen afbrydes eller stoppes, eller dosen nedsættes.
Treatment may be interrupted or stopped or the dose reduced if certain side effects develop.
Hvad er Lynparza, og hvad anvendes det til?
What is Lynparza and what is it used for?
Hvorfor er Lynparza godkendt i EU?
Why is Lynparza authorised in the EU?
Lynparza var effektivt i et studie med 302 patienter med HER2-negativ brystkræft med BRCA1/2mutationer, hvis kræft havde bredt sig.
Lynparza was effective in a study involving 302 patients with HER2-negative breast cancer with BRCA1/2 mutations whose cancer had spread.
• behandling af brystkræft, som er HER2-negativ, og som har bredt sig ud over det oprindelige område hos patienter med mutationer i BRCA1- eller BRCA2-genet, der er blevet behandlet med visse brystkræftlægemidler (medmindre disse lægemidler ikke var egnede).
• treatment of breast cancer which is HER2-negative and that has spread beyond the original site in patients with mutations in BRCA1 or BRCA2 genes who have been treated with certain breast cancer medicines (unless these medicines were not suitable).
Hvilke risici er der forbundet med Lynparza?
What are the risks associated with Lynparza?
Ved æggestok-, æggeleder- eller bughindekræft kan Lynparza også udskyde den næste serie af platinbaseret kemoterapi.
In ovarian, fallopian tube or peritoneal cancers, Lynparza can also delay the next cycle of platinum chemotherapy.
Den fuldstændige liste over bivirkninger og begrænsninger med Lynparza fremgår af indlægssedlen.
For the full list of side effects and restrictions with Lynparza, see the package leaflet.
De patienter, der blev behandlet med Lynparza, levede gennemsnitligt i 7,0 måneder uden forværring af sygdommen, sammenholdt med 4,2 måneder for de patienter, der blev behandlet med et andet kræftlægemiddel, som lægen havde valgt.
Patients treated with Lynparza lived on average 7.0 months without their disease getting worse compared with 4.2 months for patients treated with the doctor's choice of another cancer medicine.